

Phase I Study of TBI-2001 for Patients with Relapsed or Refractory CD19+ B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

Project duration: 2025-3-9 to 2027-6-30

Targeted cancer type:

Leukemia and Lymphoma

BioCanRx funding will support an additional group of patients to be treated on the team's ongoing clinical trial of their made-in-Canada CAR T cell therapy, and to determine the best dose of CAR T cells, how to predict side effects, and how well the therapy will work.

BioCanRx Contribution:

\$674,295

Biotherapeutic:

Adoptive cell therapy

Key Investigator:

Project lead:

Dr. Marcus Butler



2

Partners

The Princess Margaret
Cancer Foundation 



About the project:

Chimeric antigen receptor T cell (CAR T cell) therapy is based on modifying white blood cells in the lab so that these cells can fight cancer. Infusing these CAR T cells into patients with cancer has shown great success as a therapy for some types of cancers. However in some patients, the cancer eventually returns. To improve this therapy, researchers at the Princess Margaret Cancer Centre in Toronto have discovered a new technology that can make CAR T cells better at fighting cancer. This therapy is now

being evaluated in a clinical trial for Canadian patients. The results in the initial group of patients are promising.

BioCanRx funding will support treating additional groups of patients. At the end of this trial, the best dose of CAR T cells will be identified for further evaluation in the clinic, and insights will be gained into how to predict side effects and how well the therapy will work.



-  Research
-  Virus Manufacturing
-  Cell Manufacturing
-  Clinical Trial Site
-  Industry Collaborator
-  Core Facility (research services)
- 

Research:

University Health Network, Toronto, ON
Dr. Marcus Butler, Dr. Christine Chen,
Dr. John Kuruvilla, Dr. Ben Wang

Cell Manufacturing:

University Health Network,
Toronto, ON
Dr. Linh Nguyen

Key Deliverables

1. Obtain data to advance to the next phase of TBI-2001 clinical development
2. Complete phase I safety follow-up and clinical data collection to the End of Study visits
3. Complete biomarker analysis

The power to kill cancer lies within us. Let's tell our bodies how.